The Accelerating Medicines Partnership (AMP) program, a public-private effort aimed at improving the identification of drug targets and speed the development of new drugs. Participants include the National Institutes of Health (NIH), Foundation for NIH, biopharmaceutical firms as well as non-profit organizations
The NIH announced on February 21, 2018 in the NIH News Release the release of AMP data from ImmPort. Data from the Lupus and Rheumatoid Arthritis (AMP/SLE) pilot projects is now available in ImmPort as SDY997, SDY998 & SDY999. Data includes clinical assessments, lab tests and mechanistic assay data (CyTOF, Flow Cytometry, RNA sequencing).
Details about the AMP program, data providers, publications and shared data can be found on the ImmPort AMP Resource page (link to AMP resource page)